Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  childhood cerebral astrocytoma/malignant glioma
Stage/Subtype:  childhood cerebral astrocytoma/malignant glioma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 30 for your search:
Start Over
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 2013-062, NCI-2013-02001, P30CA022453, NCT01987596
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ADVL0912, COG-ADVL0912, CDR0000647587, NCT00939770
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 21
Sponsor: NCI
Protocol IDs: NCI-2012-03173, CDR667932, PBTC-029B, PBTC-029, U01CA081457, UM1CA081457, NCT01089101
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: Other
Protocol IDs: 10-096, NCT01294670
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED12689, U1111-1128-5704, NCT01751308
Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 22
Sponsor: Other
Protocol IDs: 1202012214, NCT01884740
PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 3 to 30
Sponsor: NCI
Protocol IDs: 150093, 15-C-0093, NCT02390752
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 21
Sponsor: Other
Protocol IDs: 24549, NCT00879437
Antineoplaston Therapy in Treating Children With Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066504, BC-BT-13, NCT00003468
Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 10-206, NCT01288235
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Phase: Phase II
Type: Tissue collection/Repository, Treatment
Status: Active
Age: 3 to 21
Sponsor: Other
Protocol IDs: CC#120817, NCT01734512
A Vaccine Trial for Low Grade Gliomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 months to less than 22 years
Sponsor: Other
Protocol IDs: PRO1310086, NCT02358187
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 03-133, P30CA008748, MSKCC-03133, NCT00089245
A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: RADBEV, NCI-2011-01149, NCT00756340
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 3 to 22
Sponsor: Pharmaceutical / Industry
Protocol IDs: 07-098, NCT00634231
Lenalidomide and Radiation Therapy in Treating Young Patients With Pontine Glioma or High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 19 at diagnosis
Sponsor: NCI
Protocol IDs: NCI-2011-02539, 10-C-0219, CDR0000687467, NCI-10-C-0219, 8449, NCT01226940
Photodynamic Therapy (PDT) for Brain Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: 163588-1, NCT01682746
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: NCI, Other
Protocol IDs: PBTC-042, U01CA081457, NCT02255461
Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 2 to 25
Sponsor: Other
Protocol IDs: 2005P001629, NCT01115777
A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
Phase: No phase specified
Type: Treatment
Status: Active
Age: 19 months to 20 years
Sponsor: Other
Protocol IDs: PRO08030085, NCT01130077
Start Over